Heart Failure,Congestive Clinical Trial
Official title:
Pilot Study of Preoperative Nicotinamide Riboside (Vitamin B3) Supplementation in Patients Undergoing Elective Left Ventricular Assist Device (LVAD) Implantation
While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR increases NAD+ levels or improves mitochondrial function in human hearts. This Pilot Study is designed to obtain feasibility data for a planned, larger study testing the hypothesis that oral NR supplementation will increase myocardial NAD+ levels and improve cardiomyocyte mitochondrial function in participants with advanced heart failure planned for elective left ventricular assist device (LVAD) implantation. To demonstrate safety and feasibility of NR in this patient population, the investigators propose to enroll 5 participants planned for LVAD implantation in a Pilot Study of NR in which participants will receive NR, up-titrated over 3 days to a final NR dose of 1000mg twice daily. Blood and myocardial tissue analyses collected previously from age- and gender-matched LVAD recipients will serve as controls.
This Pilot Study will examine the following Aims:
Aim 1: Enroll 5 participants scheduled for elective left ventricular assist device (LVAD)
placement into an open-label study of nicotinamide riboside (NR).
a. Participants will have labs (including safety panels) drawn at baseline (Day 1), then
receive escalating doses of NR to a maximum dose of 1000mg twice daily by Day 3. Participants
will be continued on NR at 1000mg twice daily until LVAD implantation surgery.
On the morning of LVAD implantation Surgery (Day 5 or later), participants will have final
labs drawn. Samples of fresh cardiac tissue removed from the left ventricular apex during
LVAD implantation surgery will be collected in the operating room. The primary analyses will
be performed on NR-treated participants who were on the maximum NR dose of 1000mg twice daily
for at least 2 days prior to LVAD implantation surgery. The maximum duration of NR
administration will be capped at 14 days. If the surgery doesn't happen by then, the
participant will be withdrawn from the study.
Aim 2: Determine the effect of NR (as compared to historical controls) on levels of the
oxidized and reduced forms of nicotine-adenine dinucleotide (NAD+ and NADH, respectively),
mitochondrial function and its regulation through modifications of the epigenome in the
failing myocardium.
1. Measure NAD+ and NADH levels in the blood and myocardium of the participants.
2. Assess mitochondrial morphology and function in cardiac tissue using, respectively,
electron microscopy (EM) and isolated mitochondria.
3. Determine protein acetylation in the mitochondrial and non-mitochondrial compartments
and changes in nuclear gene regulation.
Aim 3: Test the hypothesis that NR improves mitochondrial function and reduces inflammatory
response in heart failure (HF) patients receiving NR (as compared to historical controls).
1. Measure mitochondrial function in peripheral blood mononucleated cells (PBMC).
2. Determine the inflammatory response in PBMC.
3. Compare effects on the circulating inflammasome vs. myocardial inflammation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03519477 -
Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
|
N/A | |
Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
Recruiting |
NCT05227872 -
PVF in Decongestion of Heart Failure
|
||
Recruiting |
NCT05543720 -
Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study
|
N/A | |
Completed |
NCT04572425 -
Virtual Reality for Pain Management in Advanced Heart Failure
|
N/A | |
Recruiting |
NCT03202329 -
Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery
|
N/A | |
Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A | |
Recruiting |
NCT02672618 -
Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology
|
N/A | |
Recruiting |
NCT04179643 -
NAN-101 in Patients With Class III Heart Failure
|
Phase 1 | |
Completed |
NCT04129658 -
Heart Failure in Southern Sweden
|
||
Not yet recruiting |
NCT05591443 -
Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
|
||
Completed |
NCT03387813 -
Hemodynamic-GUIDEd Management of Heart Failure
|
N/A | |
Completed |
NCT04628325 -
Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
|
Phase 3 | |
Completed |
NCT03187470 -
Left Ventricular Dyssynchrony in Multipole Pacing
|
N/A | |
Completed |
NCT03385837 -
Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
|
||
Completed |
NCT04281849 -
Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program
|
N/A | |
Not yet recruiting |
NCT04403659 -
Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study
|
N/A | |
Terminated |
NCT04142788 -
RELieving Increasing oEdema Due to Heart Failure
|
Phase 4 | |
Active, not recruiting |
NCT04283994 -
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
|
N/A | |
Completed |
NCT03722069 -
Dietary Sodium Intake in Acute Heart Failure
|
N/A |